Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study
- PMID: 40247595
- DOI: 10.1111/jdv.20699
Five-year drug survival of dupilumab in atopic dermatitis: Italian landscape AD real-world study
References
REFERENCES
-
- Boesjes CM, Kamphuis E, de Graaf M, Spekhorst LS, Haeck I, van der Gang LF, et al. Long‐term effectiveness and reasons for discontinuation of Dupilumab in patients with atopic dermatitis. JAMA Dermatol. 2024;160(10):1044–1055. https://doi.org/10.1001/jamadermatol.2024.2517
-
- Wollenberg A, Kinberger M, Arents B, Aszodi N, Avila Valle G, Barbarot S, et al. European guideline (EuroGuiDerm) on atopic eczema: part I‐systemic therapy. J Eur Acad Dermatol Venereol. 2022;36(9):1409–1431. https://doi.org/10.1111/jdv.18345
-
- Gargiulo L, Ibba L, Malagoli P, Burroni AG, Chiricozzi A, Dapavo P, et al. Management of patients affected by moderate‐to‐severe atopic dermatitis with JAK inhibitors in real‐world clinical practice: an Italian Delphi consensus. Dermatol Ther. 2024;14(4):919–932. https://doi.org/10.1007/s13555‐024‐01135‐x
-
- European Medicines Agency. Dupixent (dupilumab): summary of product characteristics; 2017. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/dupixent. [Accessed 29 October 2024]
-
- Agenzia Italiana del Farmaco (AIFA). Dupixent (dupilumab). Available from: https://www.aifa.gov.it/documents/20142/961234/Determina_646‐2024_Dupilu... [Accessed 2025 January 28]
Publication types
LinkOut - more resources
Full Text Sources